Nanotechnology Applications for Glioblastoma

Neurosurgery Clinics of North America

Volumn 23, Issue 3, 2012, Pages 439-449

  Nduom, Edjah K ^a   Bouras, Alexandros ^a   Kaluzova, Milota ^a   Hadjipanayis, Costas G ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Convection enhanced delivery; EGFR; Glioblastoma; Magnetic nanoparticles; Malignant brain tumors; MRI; Nanoparticles; Thermotherapy

Indexed keywords

ANTINEOPLASTIC AGENT; GOLD NANOPARTICLE; MAGNETIC NANOPARTICLE; NANOPARTICLE;

BRACHYTHERAPY; CANCER INFILTRATION; CANCER RECURRENCE; CANCER THERAPY; DIAGNOSTIC IMAGING; DRUG FORMULATION; DRUG TARGETING; GENE DELIVERY SYSTEM; GLIOBLASTOMA; HUMAN; HYPERTHERMIC THERAPY; MINIMAL RESIDUAL DISEASE; NANOTECHNOLOGY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; REVIEW; TREATMENT RESPONSE;

BRACHYTHERAPY; BRAIN NEOPLASMS; CONTRAST MEDIA; DRUG DELIVERY SYSTEMS; GENE TRANSFER TECHNIQUES; GLIOBLASTOMA; HUMANS; NANOPARTICLES; NANOTECHNOLOGY; PHOTOTHERAPY;

EID: 84862985488     PISSN: 10423680     EISSN: 15581349     Source Type: Journal    
DOI: 10.1016/j.nec.2012.04.006     Document Type: Review

References (132)

1. Brat D.J., Prayson R.A., Ryken T.C., et al. Diagnosis of malignant glioma: role of neuropathology. J Neurooncol 2008, 89:287-311.
2. Stupp R., Mason W.P., van den Bent M.J., et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005, 352:987-996.
3. Legler J.M., Ries L.A., Smith M.A., et al. Cancer surveillance series [corrected]: brain and other central nervous system cancers: recent trends in incidence and mortality. J Natl Cancer Inst 1999, 91:1382-1390.
4. Brem H., Piantadosi S., Burger P.C., et al. Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. The Polymer-brain Tumor Treatment Group. Lancet 1995, 345:1008-1012.
5. Vredenburgh J.J., Desjardins A., Herndon J.E., et al. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol 2007, 25:4722-4729.
6. Kelly P.J., Daumas-Duport C., Kispert D.B., et al. Imaging-based stereotaxic serial biopsies in untreated intracranial glial neoplasms. J Neurosurg 1987, 66:865-874.
7. Demuth T., Berens M.E. Molecular mechanisms of glioma cell migration and invasion. J Neurooncol 2004, 70:217-228.
8. Hayashi C., Ryozi U., Tasaki A. Ultra-fine particles: exploratory science and technology 1997, Noyes Publications, Westwood (NJ), p. 2.
9. Maier-Hauff K., Ulrich F., Nestler D., et al. Efficacy and safety of intratumoral thermotherapy using magnetic iron-oxide nanoparticles combined with external beam radiotherapy on patients with recurrent glioblastoma multiforme. J Neurooncol 2011, 103(2):317-324.
10. Liu L., Venkatraman S.S., Yang Y.Y., et al. Polymeric micelles anchored with TAT for delivery of antibiotics across the blood-brain barrier. Biopolymers 2008, 90:617-623.
11. Loo C., Lin A., Hirsch L., et al. Nanoshell-enabled photonics-based imaging and therapy of cancer. Technol Cancer Res Treat 2004, 3:33-40.
12. Xing Y., Chaudry Q., Shen C., et al. Bioconjugated quantum dots for multiplexed and quantitative immunohistochemistry. Nat Protoc 2007, 2:1152-1165.
13. Provenzale J.M., Silva G.A. Uses of nanoparticles for central nervous system imaging and therapy. AJNR Am J Neuroradiol 2009, 30:1293-1301.
14. Jain T.K., Richey J., Strand M., et al. Magnetic nanoparticles with dual functional properties: drug delivery and magnetic resonance imaging. Biomaterials 2008, 29:4012-4021.
15. Sun C., Lee J.S., Zhang M. Magnetic nanoparticles in MR imaging and drug delivery. Adv Drug Deliv Rev 2008, 60:1252-1265.
16. Corot C., Robert P., Idee J.M., et al. Recent advances in iron oxide nanocrystal technology for medical imaging. Adv Drug Deliv Rev 2006, 58:1471-1504.
17. Lodhia J., Mandarano G., Ferris N., et al. Development and use of iron oxide nanoparticles (Part 1): synthesis of iron oxide nanoparticles for MRI. Biomed Imaging Interv J 2010, 6:e12.
18. Thorek D.L., Chen A.K., Czupryna J., et al. Superparamagnetic iron oxide nanoparticle probes for molecular imaging. Ann Biomed Eng 2006, 34:23-38.
19. Weissleder R., Elizondo G., Wittenberg J., et al. Ultrasmall superparamagnetic iron oxide: characterization of a new class of contrast agents for MR imaging. Radiology 1990, 175:489-493.
20. Pan D., Caruthers S.D., Hu G., et al. Ligand-directed nanobialys as theranostic agent for drug delivery and manganese-based magnetic resonance imaging of vascular targets. J Am Chem Soc 2008, 130:9186-9187.
21. Na H.B., Lee J.H., An K., et al. Development of a T1 contrast agent for magnetic resonance imaging using MnO nanoparticles. Angew Chem Int Ed Engl 2007, 46:5397-5401.
22. Bridot J.L., Faure A.C., Laurent S., et al. Hybrid gadolinium oxide nanoparticles: multimodal contrast agents for in vivo imaging. J Am Chem Soc 2007, 129:5076-5084.
23. Bourrinet P., Bengele H.H., Bonnemain B., et al. Preclinical safety and pharmacokinetic profile of ferumoxtran-10, an ultrasmall superparamagnetic iron oxide magnetic resonance contrast agent. Invest Radiol 2006, 41:313-324.
24. Aime S., Caravan P. Biodistribution of gadolinium-based contrast agents, including gadolinium deposition. J Magn Reson Imaging 2009, 30:1259-1267.
25. Abraham J.L., Thakral C. Tissue distribution and kinetics of gadolinium and nephrogenic systemic fibrosis. Eur J Radiol 2008, 66:200-207.
26. Varallyay P., Nesbit G., Muldoon L.L., et al. Comparison of two superparamagnetic viral-sized iron oxide particles ferumoxides and ferumoxtran-10 with a gadolinium chelate in imaging intracranial tumors. AJNR Am J Neuroradiol 2002, 23:510-519.
27. Neuwelt E.A., Varallyay C.G., Manninger S., et al. The potential of ferumoxytol nanoparticle magnetic resonance imaging, perfusion, and angiography in central nervous system malignancy: a pilot study. Neurosurgery 2007, 60:601-611. [discussion: 611-2].
28. Neuwelt E.A., Hamilton B.E., Varallyay C.G., et al. Ultrasmall superparamagnetic iron oxides (USPIOs): a future alternative magnetic resonance (MR) contrast agent for patients at risk for nephrogenic systemic fibrosis (NSF)?. Kidney Int 2009, 75:465-474.
29. Moore A., Marecos E., Bogdanov A., et al. Tumoral distribution of long-circulating dextran-coated iron oxide nanoparticles in a rodent model. Radiology 2000, 214:568-574.
30. Zimmer C., Weissleder R., Poss K., et al. MR imaging of phagocytosis in experimental gliomas. Radiology 1995, 197:533-538.
31. Villanueva A., Canete M., Roca A.G., et al. The influence of surface functionalization on the enhanced internalization of magnetic nanoparticles in cancer cells. Nanotechnology 2009, 20:115103.
32. Rhyner M.N., Smith A.M., Gao X., et al. Quantum dots and multifunctional nanoparticles: new contrast agents for tumor imaging. Nanomedicine (Lond) 2006, 1:209-217.
33. Peng X.H., Qian X., Mao H., et al. Targeted magnetic iron oxide nanoparticles for tumor imaging and therapy. Int J Nanomedicine 2008, 3:311-321.
34. Remsen L.G., McCormick C.I., Roman-Goldstein S., et al. MR of carcinoma-specific monoclonal antibody conjugated to monocrystalline iron oxide nanoparticles: the potential for noninvasive diagnosis. AJNR Am J Neuroradiol 1996, 17:411-418.
35. Hadjipanayis C.G., Machaidze R., Kaluzova M., et al. EGFRvIII antibody-conjugated iron oxide nanoparticles for magnetic resonance imaging-guided convection-enhanced delivery and targeted therapy of glioblastoma. Cancer Res 2010, 70:6303-6312.
36. Soroceanu L., Gillespie Y., Khazaeli M.B., et al. Use of chlorotoxin for targeting of primary brain tumors. Cancer Res 1998, 58:4871-4879.
37. Lyons S.A., O'Neal J., Sontheimer H. Chlorotoxin, a scorpion-derived peptide, specifically binds to gliomas and tumors of neuroectodermal origin. Glia 2002, 39:162-173.
38. Deshane J., Garner C.C., Sontheimer H. Chlorotoxin inhibits glioma cell invasion via matrix metalloproteinase-2. J Biol Chem 2003, 278:4135-4144.
39. Veiseh O., Gunn J.W., Kievit F.M., et al. Inhibition of tumor-cell invasion with chlorotoxin-bound superparamagnetic nanoparticles. Small 2009, 5:256-264.
40. Veiseh O., Sun C., Fang C., et al. Specific targeting of brain tumors with an optical/magnetic resonance imaging nanoprobe across the blood-brain barrier. Cancer Res 2009, 69:6200-6207.
41. Veiseh O., Sun C., Gunn J., et al. Optical and MRI multifunctional nanoprobe for targeting gliomas. Nano Lett 2005, 5:1003-1008.
42. McFerrin M.B., Sontheimer H. A role for ion channels in glioma cell invasion. Neuron Glia Biol 2006, 2:39-49.
43. Christian S., Pilch J., Akerman M.E., et al. Nucleolin expressed at the cell surface is a marker of endothelial cells in angiogenic blood vessels. J Cell Biol 2003, 163:871-878.
44. Reddy G.R., Bhojani M.S., McConville P., et al. Vascular targeted nanoparticles for imaging and treatment of brain tumors. Clin Cancer Res 2006, 12:6677-6686.
45. Tomanek B., Iqbal U., Blasiak B., et al. Evaluation of brain tumor vessels specific contrast agents for glioblastoma imaging. Neuro Oncol 2012, 14:53-63.
46. Faucher L., Guay-Begin A.A., Lagueux J., et al. Ultra-small gadolinium oxide nanoparticles to image brain cancer cells in vivo with MRI. Contrast Media Mol Imaging 2011, 6:209-218.
47. Mowat P., Mignot A., Rima W., et al. In vitro radiosensitizing effects of ultrasmall gadolinium based particles on tumour cells. J Nanosci Nanotechnol 2011, 11:7833-7839.
48. Fillmore H.L., Shultz M.D., Henderson S.C., et al. Conjugation of functionalized gadolinium metallofullerenes with IL-13 peptides for targeting and imaging glial tumors. Nanomedicine (Lond) 2011, 6:449-458.
49. Leung K. TAMRA-IL-13-Conjugated functionalized gadolinium metallofullerene (Gd3N@C80(OH)-26(CH2CH2COOH)-16), Molecular Imaging and Contrast Agent Database (MICAD). Bethesda (MD): National Library of Medicine (US), NCBI; 2004-2009. Available at: . Accessed April 27, 2012. http://micad.nih.gov.
50. Lu Y.J., Wei K.C., Ma C.C., et al. Dual targeted delivery of doxorubicin to cancer cells using folate-conjugated magnetic multi-walled carbon nanotubes. Colloids Surf B Biointerfaces 2012, 89:1-9.
51. Sanai N., Polley M.Y., McDermott M.W., et al. An extent of resection threshold for newly diagnosed glioblastomas. J Neurosurg 2011, 115:3-8.
52. Senft C., Franz K., Blasel S., et al. Influence of iMRI-guidance on the extent of resection and survival of patients with glioblastoma multiforme. Technol Cancer Res Treat 2010, 9:339-346.
53. Mehdorn H.M., Schwartz F., Dawirs S., et al. High-field iMRI in glioblastoma surgery: improvement of resection radicality and survival for the patient?. Acta Neurochir Suppl 2011, 109:103-106.
54. Willems P.W., Taphoorn M.J., Burger H., et al. Effectiveness of neuronavigation in resecting solitary intracerebral contrast-enhancing tumors: a randomized controlled trial. J Neurosurg 2006, 104:360-368.
55. Hadjipanayis C.G., Jiang H., Roberts D.W., et al. Current and future clinical applications for optical imaging of cancer: from intraoperative surgical guidance to cancer screening. Semin Oncol 2011, 38:109-118.
56. Van Meir E.G., Hadjipanayis C.G., Norden A.D., et al. Exciting new advances in neuro-oncology: the avenue to a cure for malignant glioma. CA Cancer J Clin 2010, 60:166-193.
57. Moore G.E., Peyton W.T., French L.A., et al. The clinical use of fluorescein in neurosurgery; the localization of brain tumors. J Neurosurg 1948, 5:392-398.
58. Britz G.W., Ghatan S., Spence A.M., et al. Intracarotid RMP-7 enhanced indocyanine green staining of tumors in a rat glioma model. J Neurooncol 2002, 56:227-232.
59. Ozawa T., Britz G.W., Kinder D.H., et al. Bromophenol blue staining of tumors in a rat glioma model. Neurosurgery 2005, 57:1041-1047. [discussion: 1041-7].
60. Stummer W., Pichlmeier U., Meinel T., et al. Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial. Lancet Oncol 2006, 7:392-401.
61. Eljamel M.S., Goodman C., Moseley H. ALA and Photofrin fluorescence-guided resection and repetitive PDT in glioblastoma multiforme: a single centre Phase III randomised controlled trial. Lasers Med Sci 2008, 23:361-367.
62. Kircher M.F., Mahmood U., King R.S., et al. A multimodal nanoparticle for preoperative magnetic resonance imaging and intraoperative optical brain tumor delineation. Cancer Res 2003, 63:8122-8125.
63. Aboody K.S., Brown A., Rainov N.G., et al. Neural stem cells display extensive tropism for pathology in adult brain: evidence from intracranial gliomas. Proc Natl Acad Sci U S A 2000, 97:12846-12851.
64. Yang S.Y., Liu H., Zhang J.N. Gene therapy of rat malignant gliomas using neural stem cells expressing IL-12. DNA Cell Biol 2004, 23:381-389.
65. Benedetti S., Pirola B., Pollo B., et al. Gene therapy of experimental brain tumors using neural progenitor cells. Nat Med 2000, 6:447-450.
66. Hamada H., Kobune M., Nakamura K., et al. Mesenchymal stem cells (MSC) as therapeutic cytoreagents for gene therapy. Cancer Sci 2005, 96:149-156.
67. Wu X., Hu J., Zhou L., et al. In vivo tracking of superparamagnetic iron oxide nanoparticle-labeled mesenchymal stem cell tropism to malignant gliomas using magnetic resonance imaging. Laboratory investigation. J Neurosurg 2008, 108:320-329.
68. Tang C., Russell P.J., Martiniello-Wilks R., et al. Concise review: Nanoparticles and cellular carriers-allies in cancer imaging and cellular gene therapy?. Stem Cells 2010, 28:1686-1702.
69. Arbab A.S., Janic B., Knight R.A., et al. Detection of migration of locally implanted AC133+ stem cells by cellular magnetic resonance imaging with histological findings. FASEB J 2008, 22:3234-3246.
70. Goldstein L.S., Dewhirst M.W., Repacholi M., et al. Summary, conclusions and recommendations: adverse temperature levels in the human body. Int J Hyperthermia 2003, 19:373-384.
71. Hildebrandt B., Wust P., Ahlers O., et al. The cellular and molecular basis of hyperthermia. Crit Rev Oncol Hematol 2002, 43:33-56.
72. Wust P., Hildebrandt B., Sreenivasa G., et al. Hyperthermia in combined treatment of cancer. Lancet Oncol 2002, 3:487-497.
73. Suto R., Srivastava P.K. A mechanism for the specific immunogenicity of heat-shock protein-chaperoned peptides. Science 1995, 269:1585-1588.
74. Santos-Marques M.J., Carvalho F., Sousa C., et al. Cytotoxicity and cell signalling induced by continuous mild hyperthermia in freshly isolated mouse hepatocytes. Toxicology 2006, 224:210-218.
75. Vanpouille-Box C., Lacoeuille F., Belloche C., et al. Tumor eradication in rat glioma and bypass of immunosuppressive barriers using internal radiation with (188)Re-lipid nanocapsules. Biomaterials 2011, 32:6781-6790.
76. Hirsch L.R., Gobin A.M., Lowery A.R., et al. Metal nanoshells. Ann Biomed Eng 2006, 34:15-22.
77. Bernardi R.J., Lowery A.R., Thompson P.A., et al. Immunonanoshells for targeted photothermal ablation in medulloblastoma and glioma: an in vitro evaluation using human cell lines. J Neurooncol 2008, 86:165-172.
78. Baek S.K., Makkouk A.R., Krasieva T., et al. Photothermal treatment of glioma; an in vitro study of macrophage-mediated delivery of gold nanoshells. J Neurooncol 2011, 104:439-448.
79. Hadjipanayis C.G., Bonder M.J., Balakrishnan S., et al. Metallic iron nanoparticles for MRI contrast enhancement and local hyperthermia. Small 2008, 4:1925-1929.
80. Mehdaoui B., Meffre A., Carrey J., et al. Optimal size of nanoparticles for magnetic hyperthermia: a combined theoretical and experiemental study. Adv Funct Mater 2011, 21:4573-4581.
81. Dennis C.L., Jackson A.J., Borchers J.A., et al. Nearly complete regression of tumors via collective behavior of magnetic nanoparticles in hyperthermia. Nanotechnology 2009, 20:395103.
82. Lee J.H., Jang J.T., Choi J.S., et al. Exchange-coupled magnetic nanoparticles for efficient heat induction. Nat Nanotechnol 2011, 6:418-422.
83. Wijaya A., Brown K.A., Alper J.D., et al. Magnetic field heating study of Fe-doped Au nanoparticles. J Magn Magn Mater 2007, 309:15-19.
84. Sharma R., Chen C.J. Newer nanoparticles in hyperthermia treatment and thermometry. J Nanopart Res 2009, 11:671-689.
85. Pradhan P., Giri J., Samanta G., et al. Comparative evaluation of heating ability and biocompatibility of different ferrite-based magnetic fluids for hyperthermia application. J Biomed Mater Res B Appl Biomater 2007, 81:12-22.
86. Kim D.H., Thai Y.T., Nikles D.E., et al. Heating of aqueous dispersions containing MnFe(2)O(4) nanoparticles by radio-frequency magnetic field induction. IEEE Trans Magn 2009, 45:64-70.
87. Kaman O., Pollert E., Veverka P., et al. Silica encapsulated manganese perovskite nanoparticles for magnetically induced hyperthermia without the risk of overheating. Nanotechnology 2009, 20:275610.
88. Atsarkin V.A., Levkin L.V., Posvyanskiy V.S., et al. Solution to the bioheat equation for hyperthermia with La1-xAgyMnO3-nanoparticles: the effect of temperature autostabilization. Int J Hyperthermia 2009, 25:240-247.
89. Bae S., Lee S.W., Takemura Y., et al. Dependence of frequency and magnetic field on self-heating characteristics of NiFe2O4 nanoparticles for hyperthermia. IEEE Trans Magn 2006, 42:3566-3568.
90. Kim D.H., Lee S.H., Kim K.N., et al. Temperature change of various ferrite particles with alternating magnetic field for hyperthermic application. J Magn Magn Mater 2005, 293:320-327.
91. Kim D.H., Lee S.H., Kim K.N., et al. In vitro and in vivo characterization of various ferrites for hyperthermia in cancer-treatment. Bioceramics 2005, vol. 17:827-830. Trans Tech Publications, (Key Engineering Materials) Switzerland.
92. Huber D.L. Synthesis, properties, and applications of iron nanoparticles. Small 2005, 1:482-501.
93. Pradhan P., Giri J., Banerjee R., et al. Cellular interactions of lauric acid and dextran-coated magnetite nanoparticles. J Magn Magn Mater 2007, 311:282-287.
94. Luis Corchero J., Villaverde A. Biomedical applications of distally controlled magnetic nanoparticles. Trends Biotechnol 2009, 27:468-476.
95. Jordan A., Scholz R., Maier-Hauff K., et al. The effect of thermotherapy using magnetic nanoparticles on rat malignant glioma. J Neurooncol 2006, 78:7-14.
96. Maier-Hauff K., Rothe R., Scholz R., et al. Intracranial thermotherapy using magnetic nanoparticles combined with external beam radiotherapy: results of a feasibility study on patients with glioblastoma multiforme. J Neurooncol 2007, 81:53-60.
97. Jiang X., Xin H., Sha X., et al. PEGylated poly(trimethylene carbonate) nanoparticles loaded with paclitaxel for the treatment of advanced glioma: in vitro and in vivo evaluation. Int J Pharm 2011, 420:385-394.
98. Sawyer A.J., Saucier-Sawyer J.K., Booth C.J., et al. Convection-enhanced delivery of camptothecin-loaded polymer nanoparticles for treatment of intracranial tumors. Drug Deliv Transl Res 2011, 1:34-42.
99. Agarwal A., Mackey M.A., El-Sayed M.A., et al. Remote triggered release of doxorubicin in tumors by synergistic application of thermosensitive liposomes and gold nanorods. ACS Nano 2011, 5:4919-4926.
100. Cancer Genome Atlas Research Network Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 2008, 455:1061-1068.
101. Jin J., Bae K.H., Yang H., et al. In vivo specific delivery of c-Met siRNA to glioblastoma using cationic solid lipid nanoparticles. Bioconjug Chem 2011, 22:2568-2572.
102. Zhan C., Meng Q., Li Q., et al. Cyclic RGD-polyethylene glycol-polyethylenimine for intracranial glioblastoma-targeted gene delivery. Chem Asian J 2012, 7:91-96.
103. Shultz M.D., Wilson J.D., Fuller C.E., et al. Metallofullerene-based nanoplatform for brain tumor brachytherapy and longitudinal imaging in a murine orthotopic xenograft model. Radiology 2011, 261:136-143.
104. Nie S., Xing Y., Kim G.J., et al. Nanotechnology applications in cancer. Annu Rev Biomed Eng 2007, 9:257-288.
105. Peer D., Karp J.M., Hong S., et al. Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol 2007, 2:751-760.
106. Gref R., Minamitake Y., Peracchia M.T., et al. Biodegradable long-circulating polymeric nanospheres. Science 1994, 263:1600-1603.
107. van der Sanden B.P., Rozijn T.H., Rijken P.F., et al. Noninvasive assessment of the functional neovasculature in 9L-glioma growing in rat brain by dynamic 1H magnetic resonance imaging of gadolinium uptake. J Cereb Blood Flow Metab 2000, 20:861-870.
108. Vajkoczy P., Menger M.D. Vascular microenvironment in gliomas. J Neurooncol 2000, 50:99-108.
109. Batchelor T.T., Sorensen A.G., di Tomaso E., et al. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 2007, 11:83-95.
110. Son Y.J., Jang J.S., Cho Y.W., et al. Biodistribution and anti-tumor efficacy of doxorubicin loaded glycol-chitosan nanoaggregates by EPR effect. J Control Release 2003, 91:135-145.
111. Agemy L., Friedmann-Morvinski D., Kotamraju V.R., et al. Targeted nanoparticle enhanced proapoptotic peptide as potential therapy for glioblastoma. Proc Natl Acad Sci U S A 2011, 108:17450-17455.
112. Li J., Gu B., Meng Q., et al. The use of myristic acid as a ligand of polyethylenimine/DNA nanoparticles for targeted gene therapy of glioblastoma. Nanotechnology 2011, 22:435101.
113. Tahara K., Kato Y., Yamamoto H., et al. Intracellular drug delivery using polysorbate 80-modified poly(D, L-lactide-co-glycolide) nanospheres to glioblastoma cells. J Microencapsul 2011, 28:29-36.
114. Gelperina S., Maksimenko O., Khalansky A., et al. Drug delivery to the brain using surfactant-coated poly(lactide-co-glycolide) nanoparticles: influence of the formulation parameters. Eur J Pharm Biopharm 2010, 74:157-163.
115. Wohlfart S., Khalansky A.S., Gelperina S., et al. Efficient chemotherapy of rat glioblastoma using doxorubicin-loaded PLGA nanoparticles with different stabilizers. PLoS One 2011, 6:e19121.
116. Chang J., Paillard A., Passirani C., et al. Transferrin adsorption onto PLGA nanoparticles governs their interaction with biological systems from blood circulation to brain cancer cells. Pharm Res 2011, 29:1495-1505.
117. Chertok B., Moffat B.A., David A.E., et al. Iron oxide nanoparticles as a drug delivery vehicle for MRI monitored magnetic targeting of brain tumors. Biomaterials 2008, 29:487-496.
118. Chertok B., David A.E., Huang Y., et al. Glioma selectivity of magnetically targeted nanoparticles: a role of abnormal tumor hydrodynamics. J Control Release 2007, 122:315-323.
119. Pulfer S.K., Ciccotto S.L., Gallo J.M. Distribution of small magnetic particles in brain tumor-bearing rats. J Neurooncol 1999, 41:99-105.
120. Hynynen K., McDannold N., Vykhodtseva N., et al. Focal disruption of the blood-brain barrier due to 260-kHz ultrasound bursts: a method for molecular imaging and targeted drug delivery. J Neurosurg 2006, 105:445-454.
121. Pardridge W.M. Drug and gene delivery to the brain: the vascular route. Neuron 2002, 36:555-558.
122. Muldoon L.L., Soussain C., Jahnke K., et al. Chemotherapy delivery issues in central nervous system malignancy: a reality check. J Clin Oncol 2007, 25:2295-2305.
123. Liu H.L., Hua M.Y., Yang H.W., et al. Magnetic resonance monitoring of focused ultrasound/magnetic nanoparticle targeting delivery of therapeutic agents to the brain. Proc Natl Acad Sci U S A 2010, 107:15205-15210.
124. Bobo R.H., Laske D.W., Akbasak A., et al. Convection-enhanced delivery of macromolecules in the brain. Proc Natl Acad Sci U S A 1994, 91:2076-2080.
125. Allard E., Passirani C., Benoit J.P. Convection-enhanced delivery of nanocarriers for the treatment of brain tumors. Biomaterials 2009, 30:2302-2318.
126. Thorne R.G., Nicholson C. In vivo diffusion analysis with quantum dots and dextrans predicts the width of brain extracellular space. Proc Natl Acad Sci U S A 2006, 103:5567-5572.
127. Perlstein B., Ram Z., Daniels D., et al. Convection-enhanced delivery of maghemite nanoparticles: increased efficacy and MRI monitoring. Neuro Oncol 2008, 10:153-161.
128. Sampson J.H., Brady M.L., Petry N.A., et al. Intracerebral infusate distribution by convection-enhanced delivery in humans with malignant gliomas: descriptive effects of target anatomy and catheter positioning. Neurosurgery 2007, 60:ONS89-ONS98. [discussion: ONS98-9].
129. Varenika V., Dickinson P., Bringas J., et al. Detection of infusate leakage in the brain using real-time imaging of convection-enhanced delivery. J Neurosurg 2008, 109:874-880.
130. Sampson J.H., Archer G., Pedain C., et al. Poor drug distribution as a possible explanation for the results of the PRECISE trial. J Neurosurg 2010, 113:301-309.
131. Asthagiri A.R., Walbridge S., Heiss J.D., et al. Effect of concentration on the accuracy of convective imaging distribution of a gadolinium-based surrogate tracer. J Neurosurg 2011, 115:467-473.
132. Silva A.C., Oliveira T.R., Mamani J.B., et al. Application of hyperthermia induced by superparamagnetic iron oxide nanoparticles in glioma treatment. Int J Nanomedicine 2011, 6:591-603.